Recent Research into the Refractory Chronic Lymphocytic Leukemia(CLL)-Pipeline Review, H2 2016

Refractory Chronic Lymphocytic Leukemia(CLL)-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Leukemia that does not responded to treatment is called refractory chronic lymphocytic leukemia. Symptoms include fever and infection, abnormal bleeding, shortness of breath, weight loss and swelling of lymph nodes. Treatment includes stem cell transplantation or bone marrow transplantation.

To access full report with TOC, please visit Refractory Chronic Lymphocytic Leukemia(CLL)-Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 21, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Refractory Chronic Lymphocytic Leukemia (CLL).

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AbbVie Inc Arno Therapeutics, Inc. Astellas Pharma Inc. Astex Pharmaceuticals Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cellular Biomedicine Group, Inc. F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. Hutchison MediPharma Limited ImmunoGen, Inc. Immunomedics, Inc. Incyte Corporation Innate Pharma S.A. Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. LFB S.A. Lymphocyte Activation Technologies, S.A. Medicenna Therapeutics, Inc. Millennium Pharmaceuticals Inc MorphoSys AG Novartis AG Oncternal Therapeutics, Inc. Ono Pharmaceutical Co., Ltd. Portola Pharmaceuticals, Inc. Sanofi Tragara Pharmaceuticals, Inc. Verastem, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###